Literature DB >> 27848916

Tumoral heterogeneity of breast cancer.

Aurélie Roulot1, Delphine Héquet1, Jean-Marc Guinebretière2, Anne Vincent-Salomon3, Florence Lerebours4, Coraline Dubot4, Roman Rouzier1.   

Abstract

The objective of this literature review is to describe the types of tumor heterogeneity in breast cancer and their clinical implication. Two kinds of tumor heterogeneity are described: intertumor heterogeneity and intra-tumor heterogeneity. In breast cancer, inter-tumor heterogeneity was best characterized in the 2000s thanks to high throughput analyses. These analyzes resulted in a molecular classification of breast cancers distinguishing four subtypes: Luminal A, Luminal B, HER 2+ and basal like. This variability may be observed between the primary tumor and metastases, namely the temporal intratumor heterogeneity. The average discrepancy for the progesterone receptor, estrogen, and between HER2 status appears to be 33%, 20% and 8%, respectively. It is then interesting to study the heterogeneity within the primary tumor: this spatial intra-tumor heterogeneity is poorly known. Physiopathology of intra-tumor heterogeneity light be deciphered by studies on cancer stem cells and clonal evolution model. In addition, the tumor microenvironment seems to actively contribute to this heterogeneity. The major interest to study this heterogeneity is the clinical implication that could result. While precision medicine is emerging, it is important to capture the heterogeneity of each specific tumor type. These new biological knowledge will allow us to anticipate such heterogeneity and individualize the management of breast cancer.

Entities:  

Keywords:  breast cancer; intertumor heterogeneity; intratumor heterogeneity

Mesh:

Substances:

Year:  2016        PMID: 27848916     DOI: 10.1684/abc.2016.1192

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  21 in total

1.  Circulating Tumor Cells and Breast Cancer: The Long and Winding Road Behind and Before Us.

Authors:  Jennifer K Plichta
Journal:  Ann Surg Oncol       Date:  2022-01-04       Impact factor: 5.344

2.  mRNAsi-related genes can effectively distinguish hepatocellular carcinoma into new molecular subtypes.

Authors:  Canbiao Wang; Shijie Qin; Wanwan Pan; Xuejia Shi; Hanyu Gao; Ping Jin; Xinyi Xia; Fei Ma
Journal:  Comput Struct Biotechnol J       Date:  2022-06-08       Impact factor: 6.155

3.  Integrated Analysis of Genomic and Transcriptomic Profiles Identified the Role of GTP Binding Protein-4 (GTPBP4) in Breast Cancer.

Authors:  Yiming Hu; Jiaheng Xie; Liang Chen; Qikai Tang; Wei Wei; Wenfeng Lin; Wang Du; Tinghong Xiang; Lu Yin; Jing Ji
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

4.  Tumor immunotherapy: New aspects of natural killer cells.

Authors:  Yangxi Li; Rui Sun
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

5.  Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.

Authors:  Danielle D Jandial; Lauren S Krill; Lixia Chen; Chunli Wu; Yu Ke; Jun Xie; Bang H Hoang; Xiaolin Zi
Journal:  Molecules       Date:  2017-03-14       Impact factor: 4.411

6.  Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.

Authors:  Vishnu C Ramani; Clementine A Lemaire; Melanie Triboulet; Kerriann M Casey; Kyra Heirich; Corinne Renier; José G Vilches-Moure; Rakhi Gupta; Aryana M Razmara; Haiyu Zhang; George W Sledge; Elodie Sollier; Stefanie S Jeffrey
Journal:  Breast Cancer Res       Date:  2019-08-28       Impact factor: 6.466

Review 7.  Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Francesco Maione; Daniela Montesarchio; Michele Caraglia; Luigi Paduano; Rita Santamaria; Carlo Irace
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

Review 8.  Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.

Authors:  Christopher Montemagno; Gilles Pagès
Journal:  Cancers (Basel)       Date:  2020-03-29       Impact factor: 6.639

9.  Persistent Increased Frequency of Genomic Instability in Women Diagnosed with Breast Cancer: Before, during, and after Treatments.

Authors:  Márcia Fernanda Correia Jardim Paz; André Luiz Pinho Sobral; Jaqueline Nascimento Picada; Ivana Grivicich; Antonio Luiz Gomes Júnior; Ana Maria Oliveira Ferreira da Mata; Marcus Vinícius Oliveira Barros de Alencar; Rodrigo Mendes de Carvalho; Kátia da Conceição Machado; Muhammad Torequl Islam; Ana Amélia de Carvalho Melo Cavalcante; Juliana da Silva
Journal:  Oxid Med Cell Longev       Date:  2018-06-14       Impact factor: 6.543

10.  Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR-326/FGFR1 axis.

Authors:  Jing Jiang; Hui Lin; Shenghong Shi; Ying Hong; Xianan Bai; Xuchen Cao
Journal:  Thorac Cancer       Date:  2020-10-01       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.